Eagle Pharmaceuticals (EGRX)
$45.91 0.00 (0.00%)
16:22 EDT EGRX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 681.09M
PE Ratio 22.73
Volume (Avg. Vol.)
Day's Range 45.91 - 45.91
52-Week Range 33.80 - 64.94
Dividend & Yield N/A (N/A)
EGRX Stock Predictions, Articles, and Eagle Pharmaceuticals News
- From InvestorPlace
- From the Web
An Obamacare replacement is back in the news, and these seven A-rated healthcare stocks are winners regardless of how it shakes out.
The second quarter is about making money without worrying about Washington or Wall Street. These seven are the "best of the best" stocks to buy for Q2.
The world was shocked by Donald Trump's surprise victory, but few equities will benefit as much as big pharma stocks.
This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Why Cypress Semiconductor Corporation (CY), Eagle Pharmaceuticals Inc (EGRX) and Energy Transfer Equity LP (ETE) Are 3 of Today’s Worst Stocks
Cypress Semiconductor (CY), Eagle Pharmaceuticals (EGRX) and Energy Transfer Equity (ETE) were left out of Monday's mostly market-wide rally.
The ratings of 27 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
If you're a fan of growth stocks and healthcare stocks ... well, these seven names would've done you well in 2015. A few of them could keep soaring.
From Seeking Alpha
From The Motley Fool
Eagle Pharma's TREAKISYM RTD formulation OK'd in Japan; launch expected in January 2021 (NASDAQ:EGRX)
From Seeking Alpha
Eagle Pharmaceuticals' (NASDAQ:EGRX) marketing partner, SymBio Pharmaceuticals has received regulatory approval for TREAKISYM ready-to-dilute (RTD) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.As a result, the company will receive a $5M milestone payment. Product launch is expected in January 2021.The approval covers all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia).Approval for the additional indication of r/r DLBCL is currently under review by the PMDA.
Navellier RatingsPowered by Portfolio Grader